Bayer | BAYN - Cash And Equivalent


Bayer reported EUR6.67B in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Air Liquide EUR 3.96B 2.05B Dec/2025
Akzo Nobel EUR 1.62B 66M Dec/2025
Alcon AG USD 1.58B 80M Mar/2026
Amarin USD 131.06M 3.6M Mar/2026
Arkema EUR 2.19B 235M Dec/2025
AstraZeneca USD 7.56B 1.85B Mar/2026
BASF EUR 2.67B 811M Dec/2025
Bayer EUR 6.67B 774M Dec/2025
Beiersdorf EUR 1.2B 33M Dec/2025
Corteva USD 1.96B 2.56B Mar/2026
Covestro EUR 648M 44M Dec/2025
Essilor EUR 3.54B 758M Dec/2025
Fresenius EUR 1.31B 81M Dec/2025
Fresenius Medical Care EUR 1.24B 343.37M Mar/2026
Genmab DKK 1.72B 46M Dec/2025
Givaudan CHF 603M 3M Jun/2024
GlaxoSmithKline GBP 3.44B 292M Mar/2026
GRIFOLS EUR 801M 242.31M Dec/2025
Henkel EUR 2.71B 163M Dec/2025
Hikma Pharmaceutical USD 236M 48M Jun/2025
Johnson Matthey GBP 542M 49M Jun/2024
Linde USD 3.96B 1.1B Mar/2026
Lonza CHF 719M 188M Dec/2025
Merck EUR 2.33B 77M Dec/2025
Novartis USD 6.88B 4.56B Mar/2026
Nutrien USD 777M 76M Mar/2026
Philips EUR 2.79B 882M Dec/2025
PPG Industries USD 1.57B 590M Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
SAP EUR 10.04B 1.83B Mar/2026
Solvay EUR 486M 50M Mar/2026
UCB EUR 1.57B 1.14B Dec/2024
Umicore EUR 1.56B 450.17M Dec/2025
Vinci EUR 17.25B 2.18B Dec/2025